



Akebia Therapeutics to Present at Upcoming Investor Conferences

July 29, 2024

CAMBRIDGE, Mass., July 29, 2024 /PRNewswire/ -- [Akebia Therapeutics® Inc.](#) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced participation in two investor conferences in August: BTIG virtual Biotechnology Conference, August 5-6, 2024, and Canaccord Genuity (CG) 44th Annual Growth Conference, August 13-14, 2024 in Boston.

—

- **BTIG Biotechnology Conference**

John Butler, Chief Executive Officer, will participate in a fireside chat on Tuesday, August 6, at 8:00 am EST.

- **CG 44th Annual Growth Conference**

Mr. Butler will present on Wednesday, August 14 at 8:30 a.m. EST. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at <https://ir.akebia.com> following the conference.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco

mcarrasco@akebia.com

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-upcoming-investor-conferences-302208267.html>

SOURCE Akebia Therapeutics, Inc.